Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-14 4:09 pm Sale | 2025-09-30 | 13G | Silexion Therapeutics Ltd. SLXN | Lind Global Fund III LP | 212,500 6.400% | -11,550 (-5.16%) | Filing History |
| 2025-09-23 11:17 am Purchase | 2025-09-15 | 13D | Silexion Therapeutics Ltd. SLXN | Moringa Sponsor, LP | 458,824 14.670% | 458,824 (New Position) | Filing History |
| 2025-09-18 5:47 pm Purchase | 2025-09-12 | 13G | Silexion Therapeutics Ltd. SLXN | Lind Global Fund III LP | 224,050 9.900% | 224,050 (New Position) | Filing History |
| 2025-09-17 5:14 pm Purchase | 2025-09-11 | 13G | Silexion Therapeutics Ltd. SLXN | Mitchell P. Kopin | 244,771 9.990% | 244,771 (New Position) | Filing History |
| 2025-09-15 5:23 pm Sale | 2025-09-11 | 13G | Silexion Therapeutics Ltd. SLXN | Orca Capital AG | 109,432 4.900% | -21,818 (-16.62%) | Filing History |
| 2025-09-15 5:19 pm Purchase | 2025-09-11 | 13G | Silexion Therapeutics Ltd. SLXN | Orca Capital AG | 131,250 6.200% | 131,250 (New Position) | Filing History |
| 2025-09-15 12:31 pm Purchase | 2025-09-12 | 13G | Silexion Therapeutics Ltd. SLXN | Lincoln Alternative Strategies LLC | 131,250 6.180% | 131,250 (New Position) | Filing History |
| 2025-06-26 4:15 pm Purchase | 2025-06-26 | 13D | Silexion Therapeutics Ltd. SLXN | Wildcat Capital Management LLC | 7,562 1.300% | 7,562 (New Position) | Filing History |
| 2025-05-13 11:36 am Purchase | 2025-03-31 | 13G | Silexion Therapeutics Ltd. SLXN | GOLDMAN SACHS GROUP INC GS | 14,130 2.400% | 6,647 (+88.83%) | Filing History |
| 2025-05-12 12:12 pm Purchase | 2025-03-31 | 13G | Silexion Therapeutics Ltd. SLXN | CVI Investments, Inc. | 30,435 4.900% | 7,835 (+34.67%) | Filing History |
| 2025-02-10 5:31 pm Purchase | 2024-12-31 | 13G | Silexion Therapeutics Ltd. SLXN | GOLDMAN SACHS GROUP INC GS | 7,483 6.600% | 7,483 (New Position) | Filing History |
| 2025-01-23 12:19 pm Purchase | 2025-01-15 | 13G | Silexion Therapeutics Ltd. SLXN | CVI Investments, Inc. | 22,600 8.500% | 22,600 (New Position) | Filing History |
| 2025-01-21 5:49 pm Purchase | 2025-01-15 | 13G | Silexion Therapeutics Ltd. SLXN | Mitchell P. Kopin | 13,988 4.990% | 13,988 (New Position) | Filing History |
| 2024-11-20 06:15 am Purchase | 2024-08-15 | 13D | Silexion Therapeutics Ltd. SLXN | Guangzhou Sino-Israel Bio-Industry Investment Fund LLP | 14,719 13.800% | 14,719 (New Position) | Filing History |
| 2024-08-22 6:44 pm Purchase | 2024-08-15 | 13D | Silexion Therapeutics Ltd. SLXN | Wildcat Capital Management LLC | 7,562 10.500% | 7,562 (New Position) | Filing History |
| 2024-08-22 5:23 pm Purchase | 2024-08-15 | 13D | Silexion Therapeutics Ltd. SLXN | Moringa Sponsor, LP | 15,308 20.800% | 15,308 (New Position) | Filing History |